Chapter 6: Neoplasia – Cancer Development and Pathophysiology

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we're tackling a really significant topic,

neoplasia.

Our goal here is to give you a clear, concise path through the essentials of cancer biology, drawing straight from the foundational sources.

It's incredibly important stuff.

I mean, the statistics are quite stark.

Cancer is the second leading cause of death in adults worldwide right behind cardiovascular disease.

And disturbingly, it's also the second leading cause for school -aged children here in the U .S.

Yeah, exactly.

So this deep dive into chapter six, neoplasia from Porth's is really about laying out the core concepts, what cancer is, its causes, how it shows up, and current approaches to treatment.

We want to make this complex topic accessible, sort of a focused review without you feeling overwhelmed.

Precisely.

We'll start with the basic definitions.

Yeah.

You know, what makes a growth dangerous.

Then we'll dig into the underlying causes, the genetics and environmental factors.

After that, we'll look at how cancer affects the whole body, how it's diagnosed and treated.

And finally, we'll touch on the specific issues around childhood cancers.

Okay, sounds like a plan.

Let's start right at the beginning then.

What does neoplasm actually mean?

How is it different from, say, normal tissue repair?

Right.

So a neoplasm is fundamentally an abnormal mass.

The key is that its growth is excessive, it's uncoordinated with the normal surrounding tissue, and it serves no useful purpose for the body.

It grows at the expense of the host, you said.

Exactly.

It's parasitic in that sense.

People often use the word tumor, and while that originally just meant swelling, in this context, neoplasm and tumor are often used pretty interchangeably.

The study of all this is oncology.

Okay.

And the naming.

I know the names often give clues about whether it's benign or malignant.

They do.

It's a convention.

Benign tumors typically have the suffix oma.

So you might hear adenoma for a benign tumor of glandular tissue or osteoma for bone.

But malignant ones.

Malignant tumors originating from epithelial tissues, and that's most cancers use the term carcinoma, like adenocarcinoma for a malignant glandular tumor.

If it arises from misenchymal tissue, like connective tissue or muscle, it's a sarcoma.

Got it.

Now, you mentioned a key difference early on.

Cell differentiation.

How does that separate benign from malignant?

That's fundamental.

Differentiation is the process where cells become specialized.

Benign tumor cells are usually well differentiated.

They still look quite a bit like the normal cells from the tissue they came from.

But malignant cells,

they lose that resemblance.

Increasingly so.

They become less well differentiated.

And in the most aggressive cancers, they exhibit anaplasia, which is basically a complete loss of differentiation.

The cells look primitive, bizarre, and bear little resemblance to the tissue of origin.

And this anaplasia, this lack of differentiation is used for grading.

Exactly.

Tumor grading is based on this.

A grade I tumor is well differentiated, looks more like normal tissue, generally less aggressive.

A grade IV tumor shows marked anaplasia, looks very abnormal, and typically behaves much more aggressively.

So appearance reflects behavior.

Benign tumors tend to grow slowly, maybe encapsulated.

Right.

They grow by expansion.

They push surrounding tissue aside, often forming a fibrous capsule around themselves.

Malignant tumors, on the other hand,

their defining feature is invasion.

Invasion?

That sounds ominous.

It is.

Instead of just pushing, they actively infiltrate and destroy the surrounding tissue.

Think of those crab -like projections.

That's actually where the word cancer comes from, the Greek karkinos for crab.

And crucially, they can metastasize.

Spread to distant sites.

Yes.

Benign tumors don't metastasize.

Malignant tumors inevitably will, unless controlled, spreading through blood and

metastasis.

You've mentioned a specific stage.

Carcinoma in situ.

What's that?

Ah, yes.

Carcinoma in situ, or CIS.

Think of it as, well, pre -invasive cancer.

The cells within the epithelial layer look cancerous.

They have the cytological features of malignancy, but they haven't broken through the basement membrane yet.

That boundary layer.

Right.

The basement membrane separates the epithelium from the underlying connective tissue.

As long as the cancer cells stay above that membrane, it's CIS.

It's localized.

Which means it's highly curable.

Potentially 100 % curable, yes.

A classic example is CIS of the uterine cervix, often detected by pap smears.

If caught at this stage, removal is usually curative because it hasn't gained the ability to invade or metastasize.

Okay, so that distinction is huge.

Now let's dive into the cell itself.

What makes a cancer cell so badly?

What are its key characteristics, its hallmarks?

Yeah, there are several key changes.

One major thing is their lifespan.

Normal cells can only divide a limited number of times before they senesce or die.

Cancer cells often bypass this.

They maintain high levels of an enzyme called telomerase.

Telomerase rebuilds the telomeres, those protective caps on the ends of chromosomes that normally shorten with each division.

By keeping telomeres long, cancer cells essentially achieve immortality.

They can

Wow, and they don't listen to signals either.

Not the normal ones, no.

They often become growth factor independent.

They might even produce their own growth factors or have receptors that are always on, telling them to divide constantly regardless of external signals.

And that thing about bumping into neighbors.

Contact inhibition.

Right, cell density dependent inhibition, or contact inhibition.

Normal cells stop dividing when they form a complete layer when they touch each other.

Cancer cells lose this.

They just keep piling up, forming disorganized clumps and masses.

They also lose anchorage dependence.

Normal cells need to be attached to a surface to grow, but cancer cells can often grow free -floating.

All of this sounds like chaos.

Does it lead to genetic mistakes?

Absolutely.

A core feature is genetic instability.

Their DNA repair mechanisms are often faulty.

This means they accumulate mutations, point mutations, insertions, deletions, and aploidy, which is having an abnormal number of chromosomes, at a much higher rate than normal cells.

This instability actually fuels further progression and resistance.

And that progression leads to metastasis.

You described it as a tough journey for the cell.

It really is.

A cell has to detach from the primary tumor, chew through the extracellular matrix, get into a blood or lymphatic vessel, survive the journey in the circulation, which is hostile, then get out of the vessel at a new site, invade that tissue, and establish a new blood supply, angiogenesis.

It's a complex cascade.

Where does the sentinel node fit into this picture?

The sentinel node is the very first lymph node that drains fluid from the site of the primary tumor.

So if cancer cells are going to spread via the lymphatics, they'll likely show up there first.

So checking that node is key for staging.

Exactly.

For cancers like breast cancer and melanoma, a sentinel node biopsy is standard.

If that node is clear, the chance of wider lymphatic spread is much lower.

If it contains cancer cells, it indicates that cancer has begun to metastasize.

And when cancer spreads through the blood, does it land randomly or are there preferred locations?

It's definitely not random.

Anatomy plays a huge role.

Think about cancers in the GI tract, colon cancer, stomach cancer.

The venous blood from these organs drains directly into the portal vein, which goes straight to the liver.

Ah, so the liver gets the first pass of potentially cancerous cells.

Precisely.

That's why the liver is such a common site for metastases from GI cancers.

Other factors include the seed and soil idea.

The cancer cell seed needs a compatible environment soil in the target organ to thrive.

The microenvironment of the metastatic site is critical.

And this brings us back to growth.

People assume cancer cells divide super fast.

Is that always the case?

Not necessarily faster in terms of cell cycle duration.

A normal cell might divide just as quickly when it's stimulated.

The difference is the proportion of cells that are actively dividing.

You mean the growth fraction.

Yes, the growth fraction.

That's the ratio of cells currently in the cell cycle dividing to the cells that are resting in the G -URO phase.

In many cancers, a much larger fraction of cells are actively dividing and fewer are resting.

They essentially skip the resting phase.

So more cells dividing at any given time means the tumor mass doubles faster.

Exactly.

That leads to a shorter doubling time for the tumor mass.

Even if individual cell cycles aren't dramatically shorter, it's about relentless, poorly controlled proliferation.

Okay, that makes sense.

Now let's connect this behavior to the root causes, the genetics.

You mentioned accelerators and brakes earlier.

Let's start with accelerators.

The proto -oncogenes.

Right.

Proto -oncogenes are perfectly normal genes that code for proteins involved in controlling cell growth and division.

Think growth factors, receptors, signaling molecules.

They're essential.

But they can become dangerous.

Yes.

If they mutate or are activated inappropriately, they become oncogenes.

An oncogene is like a stuck accelerator pedal.

It promotes cell growth even when it's not needed.

And this activation isn't always just a small typo, a point mutation.

No, there are other ways.

Gene amplification is one where the cell makes multiple extra copies of a proto -oncogene.

A classic example is HER2NU amplification in some aggressive breast cancers.

And chromosomal translocations.

You mentioned the Philadelphia chromosome.

Yes, a famous example.

In chronic myelogenous leukemia, CML, a piece of chromosome 9 swaps places with a piece of chromosome 22.

This creates a fused gene, BCR -able, on the shortened chromosome 22, which we call the Philadelphia chromosome.

And that fused gene produces a bad protein.

It produces an abnormal tyrosine kinase protein that's constantly active, driving the uncontrolled proliferation of white blood cells characteristic of CML.

Birkitt lymphoma is another example involving translocation of the CMyc gene.

Okay, so those are the accelerators stuck on.

What about the tumor suppressor genes?

These are the genes whose normal job is to restrain cell growth or trigger apoptosis programmed cell death if a cell is damaged beyond repair.

Think of RB, the retinoblastoma gene, or the very famous TP53 gene, often called the guardian of the genome.

So if these genes are damaged or lost?

Then the brakes fail.

The cell loses critical control mechanisms that would normally stop proliferation or eliminate damaged cells.

Loss of function of tumor suppressor genes removes that inhibition.

This leads into the two -hit hypothesis, doesn't it?

Especially for inherited cancers.

It does.

The idea originally proposed based on retinoblastoma studies is that you typically need two mutations, or hits, to inactivate both copies, alleles, of a tumor suppressor gene in a cell.

Why two?

Because usually having one functional copy is enough to do the job.

So in sporadic cancers, a cell needs to acquire two independent mutations in the same tumor suppressor gene.

But if you inherit one mutated non -functional copy… You're already halfway there.

Exactly.

Every cell in your body starts with only one working copy.

You only need one more hit, a single mutation, and the remaining good copy in any given cell to lose that gene's function entirely.

This explains why people with inherited mutations in genes like RB or BRCA12 have a much higher lifetime risk of developing specific cancers.

So genetics clearly plays a massive role.

But it's not the whole story, is it?

The environment is crucial, too.

How does that fit with the stages of cancer development?

Carcinogenesis.

Right.

We usually think of carcinogenesis in three stages.

First is initiation.

The first hit?

Often, yes.

Initiation is exposure to a carcinogenic agent, a chemical radiation, a virus that causes irreversible damage, a mutation in a cell's DNA.

This initiated cell isn't cancerous yet, but it's primed.

Okay, then what?

Stage two is promotion.

This involves factors called promoters that stimulate the initiated cells to proliferate and divide rapidly.

Unlike initiation, promotion is often reversible if the promoting agent is removed.

Promoters don't cause mutations themselves, but they accelerate the growth of cells that already have one.

So initiation's the spark, promotion fans the flames.

Good analogy.

Then comes progression.

This is when the cells acquire more mutations, become genetically unstable, and develop the full malignant phenotype invasiveness, metastatic potential, increased growth rate, angiogenesis.

And those initiating and promoting factors, they often come from our environment and lifestyle.

Very often.

Think about chemical carcinogens.

Tobacco smoke is a major one.

It's actually packed with both initiators, pro -carcinogens that become active carcinogens after metabolism, and promoters.

It's linked to something like 40 % of US cancer deaths.

Wow.

What about diet?

Diet is significant too.

High -fat diets, obesity, excessive alcohol consumption are linked to increased risk for various cancers.

Charred meats contain polycyclic aromatic hydrocarbons, PAHs, which are carcinogens.

And radiation.

Yes.

Ionizing radiation like from x -rays, radon gas, nuclear fallout can directly damage DNA and cause mutations, increasing risk particularly for leukemia and thyroid cancer.

Ultraviolet UV radiation from sunlight is the main cause of skin cancers like melanoma and basal cell carcinoma.

We can't forget viruses either.

Definitely not.

Several viruses are known human carcinogens.

There are four main DNA viruses.

Human papillomavirus, HPV, linked to cervical and other cancers.

Epstein -Barr virus, EBV, linked to Burkitt lymphoma and nasopharyngeal cancer.

Hepatitis B virus, HPV, linked to liver cancer.

And human herpesvirus 8, HHV8, linked to Kaposi sarcoma.

In one RNA virus.

Yes.

One RNA retrovirus.

Human T -cell leukemia virus 1, HTLV1, which is associated with a specific type of T -cell leukemia lymphoma.

So it's this complex interplay between our genes and our exposures.

Okay.

Let's shift gears to how cancer manifests in the body clinically.

Obviously, there's the direct effect of the tumor growing.

Right.

Locally, a tumor can compress nerves causing pain, erode blood vessels causing bleeding, or obstruct hollow organs like the bowel or airway.

It can also cause fluid buildup fusions in body cavities like the pleural space around the lungs or the peritoneal cavity in the abdomen.

But then there are these really strange indirect effects.

The perineoplastic syndromes.

Ah, yes.

These are fascinating and often puzzling.

Perineoplastic syndromes are symptoms that occur at sites distant from the tumor or its metastases.

And they're not caused by the direct physical presence of the tumor.

So what causes them?

They're usually caused by substances secreted by the tumor cells, hormones, like peptides, cytokines, antibodies.

For example, some lung cancers, especially small cell, can produce antidiuretic hormone, ADH, leading to SIADH, a syndrome of inappropriate ADH secretion causing water retention and low sodium levels.

Or blood clots.

Yes.

Some cancers, particularly pancreatic and lung cancers, can secrete procoagulant factors, increasing the risk of deep vein thrombosis and pulmonary embolism.

These syndromes can sometimes be the first sign of an underlying cancer.

And then there's that devastating weighting syndrome, cancer anorexia cachexia.

You mentioned it's not just starvation.

It's absolutely critical to understand this.

Cachexia affects a huge percentage of patients with advanced cancer, maybe 50 -80%.

It involves loss of appetite, anorexia, weight loss, especially muscle mass, weakness and fatigue.

But it's driven by a hypermetabolic state.

Hypermetabolic, meaning the body's burning more energy.

Yes.

Inflammatory cytokines, like tumor necrosis factor alpha, TNFA, IL -1 and IL -6, produced either by the tumor or the body's response to it, seem to drive this process.

They increase metabolic rate and promote the breakdown of muscle and fat.

That's why simply feeding the patient more calories often doesn't reverse cachexia.

It's a systemic metabolic derangement.

That sounds incredibly difficult to manage.

Other common systemic effects include fatigue and anemia.

Yes, profound fatigue is very common, often described as overwhelming and not relieved by rest.

Anemia is also frequent due to chronic bleeding, nutritional deficiencies, bone marrow suppression from treatment, or impaired red blood cell production caused by those same inflammatory cytokines.

Okay, so when cancer is suspected, how is it diagnosed and staged?

We have screening tests like pap smears and mammograms for early detection in people without symptoms.

Right, that's secondary prevention.

For diagnosis and monitoring, we often use tumor markers.

These are substances, antigens, or hormones produced by cancer cells or by the body in response to cancer that can be measured in blood, urine, or tissues.

Like PSA for prostate cancer.

Exactly.

PSA, prostate -specific antigen, is a common one.

CA125 for ovarian cancer, CEA, and AFP on caudal antigens for certain GI and germ cell tumors.

But there's a big caveat.

They aren't perfect for screening.

Generally, no.

Most tumor markers lack the sensitivity and specificity for early screening in the general population.

They can be elevated in benign conditions, and levels often only rise significantly when the cancer is already quite advanced.

Their main value is often in monitoring response to treatment or detecting recurrence in someone already diagnosed.

Gotcha.

So once cancer is diagnosed, determining the extent of spread is crucial.

That's staging.

Yes.

We talked about grading earlier, which describes the cell appearance differentiation.

Staging describes the clinical extent of the disease, how large the primary tumor is, and how far it has spread.

And the main system for that is TNM.

The TNM system is the most widely used.

T stands for the size and door extent of invasion of the primary tumor.

N indicates the involvement of regional lymph nodes.

And M signifies the presence or absence of distant metastasis.

So a T1N0M0 tumor would be small, localized, no nodes, no meds.

Correct.

Whereas something like a T4N2M1 would be a large, invasive primary tumor with extensive regional node involvement and distant metastasis.

Staging is critical because it determines prognosis and guides treatment decisions, whether the goal is cure, control, or palliation.

Let's talk treatment.

Surgery is often the first step for solid tumors.

It's the oldest form of cancer treatment and still often the most definitive for localized solid tumors.

It can be used for diagnosis, biopsy, staging, complete removal, cure, debulking, reducing tumor mass, or palliation of symptoms.

Modern surgery focuses more on function -sparing techniques, too.

Then there's radiation therapy.

How does that work?

Radiation uses high -energy X -rays or particles to damage DNA in cancer cells, leading to cell death.

The key is that rapidly dividing cells, like most cancer cells, are generally more sensitive to radiation damage than slower dividing normal cells.

But it still affects normal rapidly dividing cells, right?

It does.

That's why side effects often involve tissues with high cell turnover, like the bone marrow, leading to low blood counts, the lining of the GI tract, nausea, diarrhea, mucusitis, and skin.

Radiation can be delivered externally, teletherapy, or internally, brachytherapy, using implanted sources.

And chemotherapy is the systemic approach.

Right.

Chemo uses drugs that circulate throughout the body to kill cancer cells, primarily by interfering with cell division or DNA synthesis function.

We classify chemo drugs based on their mechanism.

Direct DNA interacting agents, like alkylating agents, directly damage DNA.

Indirect DNA interacting agents, like anti -metabolates, mimic normal molecules and get incorporated into dinRNO, disrupting synthesis.

It hits cells all over the body, which explains the systemic side effects, too.

Exactly.

Hair loss, bone marrow suppression, nausea, vomiting.

These happen because chemo effects normal rapidly dividing cells, too.

And the newer kid on the block, relatively speaking, is biotherapy or immunotherapy.

This is a really exciting area.

It leverages the body's own immune system to fight cancer.

Examples include monoclonal antibodies designed to target specific proteins on cancer cells, like Herceptin for H or 2 -positive breast cancer.

There are also cancer vaccines, like the HPV vaccine, which prevents infection by cancer causing viruses,

and using cytokines like interferon or interleukin 2 to boost the immune response generally.

Checkpoint inhibitors are another huge area here.

Okay.

Fascinating.

Before we wrap up, we need to touch on childhood cancers.

You said they're quite different from adult cancers.

Fundamentally different in many ways.

Most adult cancers arise from epithelial tissues, carcinomas.

Most childhood cancers involve the hematopoietic system, leukemias, lymphomas, the central nervous system, or connective tissues like bone and muscle sarcomas.

And many are embryonal tumors.

Yes.

These are tumors thought to arise from primitive embryonal cells that failed to differentiate properly during development.

They often have the suffix blastoma.

Examples include Wilms tumor, kidney, retinoblastoma, eye, and neuroblastoma.

Neuroblastoma.

That's the one linked to catecholamines.

Right.

Neuroblastoma arises from neural crest cells, which normally develop into parts of the sympathetic nervous system and adrenal medulla.

These tumors often secrete catecholamines, like adrenaline metabolites, which can be detected in urine and help with diagnosis.

Diagnosis can be tricky in kids, though.

It can be delayed because the early symptoms, fever, fatigue, bone pain, weight loss often mimic common childhood illnesses.

But the good news is survival rates are Yes.

Overall, survival for childhood cancer is now around 85%, which is a huge success story compared to decades ago.

Children often tolerate chemotherapy better than adults, and many childhood tumors are highly responsive to treatment.

But there's a major downside.

The late effects.

This is the critical challenge now.

The very treatments, chemotherapy, radiation, especially cranial radiation that save lives, can cause significant long -term problems, or late effects that may not appear until years or decades later.

Impaired growth and development, hormonal dysfunction like infertility, cognitive impairment, particularly after cranial radiation,

hearing loss, heart problems, and perhaps most worryingly, an increased risk of developing secondary malignancies later in life due to the initial treatment.

Managing these late effects is a huge focus in pediatric oncology survivorship.

Wow.

Okay.

So we've covered a massive amount of We started with defining neoplasia, that uncontrolled growth, differentiating benign from malignant based on differentiation and invasion.

We looked at the hallmarks of cancer cells immortality via telomerase, ignoring signals, genetic instability.

We traced the path of metastasis, highlighting the sentinel node, and discussed the genetic drivers on code genes like accelerators, tumor suppressor genes like brakes, and the two -hit hypothesis explaining inherited risk.

Then we move through carcinogenesis, initiation, promotion, progression, linking it to environmental factors like tobacco, diet, radiation, and viruses.

We covered clinical signs like perineoplastic syndromes and the crucial nature of cachexia.

Right.

And diagnosis using markers and TNM staging, leading into treatments like surgery, radiation, chemotherapy, and the growing field of immunotherapy.

Finally, the unique aspects and long -term challenges of childhood cancers.

It really underscores the complexity.

What's the final thought you want our listeners with?

I think it comes back to that balance, especially thinking about childhood cancer survivors.

We've gotten incredibly good at curing many childhood cancers, achieving that 85 % survival rate, but we do it often with therapies like cranial radiation or certain chemo agents that we know carry significant risks for severe late effects, cognitive issues, stunted growth, secondary cancers decades down the line.

So the challenge is the ongoing challenge for

and oncology research is this.

How do we refine our treatments?

How do we develop new therapies that are just as effective at curing the cancer, but without causing these devastating long -term consequences?

How do we ensure that survival comes with a high quality of life, preserving cognitive function, fertility, and long -term health for these young patients who have their whole lives ahead of them?

That's the critical frontier.

A really important point to end on.

A huge thank you for guiding us through this incredibly complex but vital chapter on neoplasia, and thank you all for joining us on the Deep Dive.